![]() | |
Clinical data | |
---|---|
Trade names | Oxbryta |
Other names | GBT440, GBT-440 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a620011 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H19N3O3 |
Molar mass | 337.379 g·mol−1 |
3D model ( JSmol) | |
| |
|
Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. [1] [3] [4] [5] [6] Voxelotor is the first hemoglobin oxygen-affinity modulator. [7] Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. [8] It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. [9] It was developed by Global Blood Therapeutics, a subsidiary of Pfizer. [10]
In November 2019, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those twelve years of age and older. [11] [12] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. [13] In December 2021, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those aged four to eleven years. [14]
Common side effects include headache, diarrhea, abdominal pain, nausea, fatigue, rash and pyrexia (fever). [11]
Voxelotor was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2019. [12] [11] [15] The FDA granted the application for voxelotor fast track designation and orphan drug designation. [11] [16]
The approval of voxelotor was based on the results of a clinical trial with 274 participants with sickle cell disease. [11] The FDA granted the approval of Oxbryta to Global Blood Therapeutics. [11] [12]
On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oxbryta, intended for the treatment of hemolytic anemia due to sickle cell disease. [17] [18] The applicant for this medicinal product is Global Blood Therapeutics Netherlands B.V. [17] [18] Voxelotor (Oxbryta) was approved for medical use in the European Union in February 2022. [2] [19]
![]() | |
Clinical data | |
---|---|
Trade names | Oxbryta |
Other names | GBT440, GBT-440 |
AHFS/ Drugs.com | Monograph |
MedlinePlus | a620011 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C19H19N3O3 |
Molar mass | 337.379 g·mol−1 |
3D model ( JSmol) | |
| |
|
Voxelotor, sold under the brand name Oxbryta, is a medication used for the treatment of sickle cell disease. [1] [3] [4] [5] [6] Voxelotor is the first hemoglobin oxygen-affinity modulator. [7] Voxelotor has been shown to have disease-modifying potential by increasing hemoglobin levels and decreasing hemolysis indicators in sickle cell patients. [8] It has a safe profile in sickle cell patients and healthy volunteers, without any dose-limiting toxicity. [9] It was developed by Global Blood Therapeutics, a subsidiary of Pfizer. [10]
In November 2019, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those twelve years of age and older. [11] [12] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. [13] In December 2021, voxelotor received accelerated approval in the United States for the treatment of sickle cell disease for those aged four to eleven years. [14]
Common side effects include headache, diarrhea, abdominal pain, nausea, fatigue, rash and pyrexia (fever). [11]
Voxelotor was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in November 2019. [12] [11] [15] The FDA granted the application for voxelotor fast track designation and orphan drug designation. [11] [16]
The approval of voxelotor was based on the results of a clinical trial with 274 participants with sickle cell disease. [11] The FDA granted the approval of Oxbryta to Global Blood Therapeutics. [11] [12]
On 16 December 2021, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Oxbryta, intended for the treatment of hemolytic anemia due to sickle cell disease. [17] [18] The applicant for this medicinal product is Global Blood Therapeutics Netherlands B.V. [17] [18] Voxelotor (Oxbryta) was approved for medical use in the European Union in February 2022. [2] [19]